Acid–Base Balance CCRN Practice Questions – Study Review

CCRN Respiratory Examination Blueprint & Core Competencies

• The CCRN specialty examination dedicates approximately $12\%$ of its content to the respiratory system, representing roughly $18$ questions.

• Testable clinical conditions encompass:

  • Acute pulmonary edema (cardiogenic and non-cardiogenic)

  • Acute pulmonary embolism (thrombus, fat embolus, and air embolus)

  • Acute respiratory distress syndrome (ARDS)

  • Acute respiratory failure (hypoxemic Type 1 and hypercapnic Type 2)

  • Acute respiratory infections, primarily pneumonia (community-acquired, hospital-acquired, and ventilator-associated)

  • Chronic obstructive pulmonary conditions: chronic bronchitis, emphysema, and asthma exacerbations

  • Status asthmaticus

  • Mechanical ventilation complications (barotrauma, volutrauma, ventilator-associated events)

  • Pleural space abnormalities: pneumothorax (simple, open, tension), hemothorax, empyema, and pleural effusion

  • Pulmonary hemorrhage

  • Pulmonary arterial hypertension (PAH)

  • Thoracic and airway trauma: fractured ribs, flail chest, pulmonary contusion, and tracheal perforation

  • Thoracic surgical procedures (wedge resection, lobectomy, pneumonectomy)

• Core testable nursing competencies and procedural actions include:

  • Comprehensive airway management and endotracheal tube stabilization

  • Assisting with bedside bronchoscopy

  • Chest tube insertion, troubleshooting, assessment of tidaling and bubbling, and drainage system management

  • Initiation, titration, and management of invasive mechanical ventilation

  • Management of non-invasive positive pressure ventilation (NIPPV) systems, including Continuous Positive Airway Pressure (CPAP) and Bi-level Positive Airway Pressure (BiPAP), as well as High-Flow Nasal Cannula (HFNC)

  • Selection and optimization of oxygen therapy delivery devices

  • Prevention of complications associated with mechanical ventilation and non-invasive positive pressure interfaces

  • Protocolized implementation of prone positioning therapy

  • Coordination of rapid sequence intubation (RSI)

  • Advanced continuous and intermittent respiratory monitoring: pulse oximetry ($\text{SpO}_2$), mixed venous oxygen saturation ($\text{SvO}_2$), and continuous waveform capnography ($\text{EtCO}_2$ / $\text{PEtCO}_2$)

  • Administration of therapeutic gases: medical oxygen, inhaled nitric oxide (iNO), helium-oxygen mixtures (Heliox), and carbon dioxide

  • Thoracentesis assistance and post-procedure monitoring

  • Tracheostomy maintenance, care, and emergency replacement

Arterial Blood Gas (ABG) Analysis, Interpretation Methodology & Practice Scenarios

• Normal Arterial Blood Gas Reference Ranges:

  • $\text{pH}$: $7.35\text{--}7.45$ (Acidic: $< 7.35$; Alkaline: $> 7.45$

  • $\text{PaCO}_2$: $35\text{--}45\,\text{mm Hg}$ (Acidic: $> 45\,\text{mm Hg}$; Alkaline: $< 35\,\text{mm Hg}$; acts as a respiratory acid)

  • $\text{HCO}_3^-$: $22\text{--}26\,\text{mEq/L}$ (Acidic: $< 22\,\text{mEq/L}$; Alkaline: $> 26\,\text{mEq/L}$; acts as a metabolic base)

  • $\text{PaO}_2$: $80\text{--}100\,\text{mm Hg}$ (evaluates oxygenation; not used to determine acid-base nomenclature)

• Systematic 4-Step Naming Method ("First, Middle, Last Name"):

  • Step 1: Determine the First Name (Compensation Status):

  • If the $\text{pH}$ is outside the normal range ($< 7.35$ or $> 7.45$), designate the primary state as uncompensated.

  • If the $\text{pH}$ is strictly within normal limits ($7.35\text{--}7.45$) and both $\text{PaCO}_2$ and $\text{HCO}_3^-$ are abnormal, designate the state as compensated (fully compensated).

  • Step 2: Determine the Last Name (Primary Acid-Base Direction):

  • If $\text{pH} < 7.35$, the condition is acidosis.

  • If $\text{pH} > 7.45$, the condition is alkalosis.

  • If the $\text{pH}$ is within the normal range ($7.35\text{--}7.45$), use the precise physiological midpoint of $7.40$ to determine which side of normal it favors:

    • $\text{pH } 7.35\text{--}7.39$ indicates compensated acidosis.

    • $\text{pH } 7.41\text{--}7.45$ indicates compensated alkalosis.

  • Step 3: Determine the Middle Name (Etiology/System):

  • Compare the $\text{PaCO}_2$ and $\text{HCO}_3^-$ to the $\text{pH}$.

  • Whichever parameter moves in the same clinical direction as the $\text{pH}$ establishes the middle name:

    • If $\text{PaCO}_2$ matches the $\text{pH}$ deviation ($\uparrow \text{PaCO}_2$ with $\downarrow \text{pH}$, or $\downarrow \text{PaCO}_2$ with $\uparrow \text{pH}$), the disorder is respiratory.

    • If $\text{HCO}_3^-$ matches the $\text{pH}$ deviation ($\downarrow \text{HCO}_3^-$ with $\downarrow \text{pH}$, or $\uparrow \text{HCO}_3^-$ with $\uparrow \text{pH}$), the disorder is metabolic.

    • If both $\text{PaCO}_2$ and $\text{HCO}_3^-$ point toward the same acid-base state, the disorder is combined (mixed).

  • Step 4: Adjust the First Name for Partial Compensation:

  • If the $\text{pH}$ remains abnormal, but the opposing regulatory system has moved outside its normal reference range in the opposite direction (attempting to counteract the primary disturbance), change the first name from uncompensated to partially compensated.

• Master ABG Practice Scenarios, Interpretations, and Walkthroughs:

  • Worked Example: $\text{pH } 7.22$, $\text{PaCO}_2\ 74\,\text{mm Hg}$, $\text{HCO}_3^-\ 24\,\text{mEq/L}$

  • $\text{pH}$ is abnormal and $< 7.35$ (acidosis). $\text{PaCO}_2$ is elevated at $74\,\text{mm Hg}$ (respiratory acid match). $\text{HCO}_3^-$ is normal ($24\,\text{mEq/L}$, indicating no renal compensation).

  • Interpretation: Uncompensated respiratory acidosis.

  • Scenario 1 (All Acidic Values Set):

  • Question: Which set contains only acidic values?

  • Options: A. $\text{pH } 7.33$, $\text{HCO}_3^-\ 18$, $\text{PaCO}_2\ 32$; B. $\text{pH } 7.05$, $\text{HCO}_3^-\ 30$, $\text{PaCO}_2\ 48$; C. $\text{pH } 7.28$, $\text{HCO}_3^-\ 18$, $\text{PaCO}_2\ 50$; D. $\text{pH } 7.46$, $\text{HCO}_3^-\ 30$, $\text{PaCO}_2\ 32$.

  • Analysis: Choice A contains alkaline $\text{PaCO}_2\ (32)$; Choice B contains alkaline $\text{HCO}_3^-\ (30)$; Choice D contains entirely alkaline values ($\text{pH } 7.46$, $\text{HCO}_3^-\ 30$, $\text{PaCO}_2\ 32$).

  • Correct Answer: C. ($\text{pH } 7.28 < 7.35$, $\text{HCO}_3^-\ 18 < 22$, and $\text{PaCO}_2\ 50 > 45$ are all acidic).

  • Scenario 2 (All Alkaline Values Set):

  • Question: Which set contains only alkaline values?

  • Options: A. $\text{pH } 7.32$, $\text{HCO}_3^-\ 26$, $\text{PaCO}_2\ 32$; B. $\text{pH } 7.50$, $\text{HCO}_3^-\ 18$, $\text{PaCO}_2\ 32$; C. $\text{pH } 7.52$, $\text{HCO}_3^-\ 18$, $\text{PaCO}_2\ 50$; D. $\text{pH } 7.46$, $\text{HCO}_3^-\ 30$, $\text{PaCO}_2\ 32$.

  • Analysis: Choice A contains acidic $\text{pH } (7.32)$; Choices B and C contain acidic $\text{HCO}_3^-\ (18)$; Choice C also contains acidic $\text{PaCO}_2\ (50)$.

  • Correct Answer: D. ($\text{pH } 7.46 > 7.45$, $\text{HCO}_3^-\ 30 > 26$, and $\text{PaCO}_2\ 32 < 35$ are all alkaline).

  • Scenario 3: $\text{pH } 7.16$, $\text{PaCO}_2\ 35\,\text{mm Hg}$, $\text{HCO}_3^-\ 14\,\text{mEq/L}$

  • $\text{pH}$ is abnormal and acidic. $\text{HCO}_3^-$ of $14\,\text{mEq/L}$ is severely deficient, matching the acidosis (metabolic). $\text{PaCO}_2$ of $35\,\text{mm Hg}$ is normal (no respiratory compensation).

  • Interpretation: Uncompensated metabolic acidosis.

  • Scenario 4: $\text{pH } 7.20$, $\text{PaCO}_2\ 82\,\text{mm Hg}$, $\text{HCO}_3^-\ 24\,\text{mEq/L}$

  • $\text{pH}$ is abnormal and acidic. $\text{PaCO}_2$ of $82\,\text{mm Hg}$ is highly elevated, matching the acidosis (respiratory). $\text{HCO}_3^-$ of $24\,\text{mEq/L}$ is within normal limits.

  • Interpretation: Uncompensated respiratory acidosis.

  • Scenario 5: $\text{pH } 7.35$, $\text{PaCO}_2\ 60\,\text{mm Hg}$, $\text{HCO}_3^-\ 31\,\text{mEq/L}$

  • $\text{pH}$ is technically in normal range ($7.35$), indicating complete compensation. Leaning acidic ($< 7.40$), pointing to primary acidosis. $\text{PaCO}_2$ of $60\,\text{mm Hg}$ is acidic (respiratory driver). $\text{HCO}_3^-$ of $31\,\text{mEq/L}$ reflects successful secondary renal base retention.

  • Interpretation: Compensated respiratory acidosis.

  • Scenario 6: $\text{pH } 7.50$, $\text{PaCO}_2\ 25\,\text{mm Hg}$, $\text{HCO}_3^-\ 18\,\text{mEq/L}$

  • $\text{pH}$ is abnormal and alkaline ($> 7.45$). $\text{PaCO}_2$ is $25\,\text{mm Hg}$ (low acid, matching alkalosis = respiratory). $\text{HCO}_3^-$ is $18\,\text{mEq/L}$ (renal elimination of base to compensate, but $\text{pH}$ has not normalized).

  • Interpretation: Partially compensated respiratory alkalosis.

  • Scenario 7: $\text{pH } 7.45$, $\text{PaCO}_2\ 50\,\text{mm Hg}$, $\text{HCO}_3^-\ 32\,\text{mEq/L}$

  • $\text{pH}$ is normal ($7.45$), leaning alkaline ($> 7.40$). $\text{HCO}_3^-$ is $32\,\text{mEq/L}$ (alkaline match = metabolic). $\text{PaCO}_2$ is $50\,\text{mm Hg}$ (hypoventilation retaining acid to bring $\text{pH}$ into range).

  • Interpretation: Compensated metabolic alkalosis.

  • Scenario 8: $\text{pH } 7.55$, $\text{PaCO}_2\ 25\,\text{mm Hg}$, $\text{HCO}_3^-\ 23\,\text{mEq/L}$

  • $\text{pH}$ is alkaline. $\text{PaCO}_2$ is low ($25\,\text{mm Hg}$, respiratory match). $\text{HCO}_3^-$ is normal ($23\,\text{mEq/L}$, no renal compensation).

  • Interpretation: Uncompensated respiratory alkalosis.

  • Scenario 9: $\text{pH } 7.20$, $\text{PaCO}_2\ 82\,\text{mm Hg}$, $\text{HCO}_3^-\ 30\,\text{mEq/L}$

  • $\text{pH}$ is acidic. $\text{PaCO}_2$ is markedly elevated ($82\,\text{mm Hg}$, respiratory match). $\text{HCO}_3^-$ is elevated ($30\,\text{mEq/L}$, attempting renal compensation but $\text{pH}$ remains abnormal).

  • Interpretation: Partially compensated respiratory acidosis.

  • Scenario 10 (Transcript Structural Note):

  • In course transcripts, chapter numbering frequently jumps from Question 9 directly to Question 11 due to marker placement inside Question 9.

  • Scenario 11: $\text{pH } 7.32$, $\text{PaCO}_2\ 35\,\text{mm Hg}$, $\text{HCO}_3^-\ 16\,\text{mEq/L}$

  • $\text{pH}$ is acidic. $\text{HCO}_3^-$ is low ($16\,\text{mEq/L}$, metabolic match). $\text{PaCO}_2$ is normal ($35\,\text{mm Hg}$, no respiratory compensation).

  • Interpretation: Uncompensated metabolic acidosis. Clinical associations include diabetic ketoacidosis (DKA), acute kidney injury (AKI), and salicylate toxicity.

  • Scenario 12: $\text{pH } 7.50$, $\text{PaCO}_2\ 44\,\text{mm Hg}$, $\text{HCO}_3^-\ 32\,\text{mEq/L}$

  • $\text{pH}$ is alkaline. $\text{HCO}_3^-$ is high ($32\,\text{mEq/L}$, metabolic match). $\text{PaCO}_2$ is normal ($44\,\text{mm Hg}$, no compensation).

  • Interpretation: Uncompensated metabolic alkalosis. Seen in severe vomiting, nasogastric suctioning, and sodium bicarbonate administration.

  • Scenario 13: $\text{pH } 7.55$, $\text{PaCO}_2\ 25\,\text{mm Hg}$, $\text{HCO}_3^-\ 22\,\text{mEq/L}$

  • $\text{pH}$ is alkaline. $\text{PaCO}_2$ is low ($25\,\text{mm Hg}$, respiratory match). $\text{HCO}_3^-$ is normal ($22\,\text{mEq/L}$, no compensation).

  • Interpretation: Uncompensated respiratory alkalosis. Driven by hyperventilation from anxiety, pain, or early respiratory failure.

  • Scenario 14: $\text{pH } 7.30$, $\text{PaCO}_2\ 50\,\text{mm Hg}$, $\text{HCO}_3^-\ 24\,\text{mEq/L}$

  • $\text{pH}$ is acidic. $\text{PaCO}_2$ is high ($50\,\text{mm Hg}$, respiratory match). $\text{HCO}_3^-$ is normal ($24\,\text{mEq/L}$, no compensation).

  • Interpretation: Uncompensated respiratory acidosis. Caused by acute hypoventilation, oversedation, or respiratory muscle fatigue.

  • Scenario 15: $\text{pH } 7.21$, $\text{PaCO}_2\ 50\,\text{mm Hg}$, $\text{HCO}_3^-\ 12\,\text{mEq/L}$

  • $\text{pH}$ is severely acidic. $\text{PaCO}_2$ of $50\,\text{mm Hg}$ is acidic. $\text{HCO}_3^-$ of $12\,\text{mEq/L}$ is acidic. Both systems actively contribute to the profound acidemia.

  • Interpretation: Combined (mixed) respiratory and metabolic acidosis.

  • Additional Part 1 / Part 2 Vignettes:

  • Patient exhibiting: $\text{pH } 7.19$, $\text{PaCO}_2\ 66\,\text{mm Hg}$, $\text{PaO}_2\ 68\,\text{mm Hg}$, $\text{HCO}_3^-\ 30\,\text{mEq/L}$.

    • Walkthrough: $\text{pH}$ is acidic; high $\text{PaCO}_2$ matches acidosis (respiratory); high $\text{HCO}_3^-$ reflects partial renal buffering.

    • Answer: Partially compensated respiratory acidosis.

  • Patient exhibiting: $\text{pH } 7.31$, $\text{PaCO}_2\ 32\,\text{mm Hg}$, $\text{PaO}_2\ 68\,\text{mm Hg}$, $\text{HCO}_3^-\ 15\,\text{mEq/L}$.

    • Walkthrough: $\text{pH}$ is acidic; low $\text{HCO}_3^-$ matches acidosis (metabolic); low $\text{PaCO}_2$ represents hyperventilation compensation.

    • Answer: Partially compensated metabolic acidosis.

Acid-Base Disorders: Pathophysiology, Causes, and Compensation Dynamics

• Mechanisms and Underlying Etiologies:

  • Respiratory Acidosis ($\text{PaCO}_2 > 45\,\text{mm Hg}$):

  • Mechanism: Alveolar hypoventilation leading to pathological carbon dioxide retention.

  • Common Causes: Late acute respiratory failure, opioid or sedative oversedation, acute drug overdoses causing central respiratory depression, tiring asthmatic or ARDS patients, severe morbid obesity (obesity hypoventilation syndrome), obstructive sleep apnea, and neuromuscular failure (Guillain-Barré syndrome, myasthenia gravis, amyotrophic lateral sclerosis).

  • Respiratory Alkalosis ($\text{PaCO}_2 < 35\,\text{mm Hg}$):

  • Mechanism: Alveolar hyperventilation blowing off carbonic acid.

  • Common Causes: Early acute respiratory failure, acute anxiety, panic attacks, severe pain, pyrexia/fever, systemic sepsis, hypoxemia, pulmonary embolism, and iatrogenic overventilation (ventilator rate or tidal volume set too high).

  • Metabolic Acidosis ($\text{HCO}_3^- < 22\,\text{mEq/L}$):

  • Mechanism: Excessive accumulation of non-volatile organic acids or inability of the renal tubules to excrete hydrogen ions / regenerate bicarbonate.

  • Common Causes: Diabetic ketoacidosis (DKA), acute kidney injury (AKI), end-stage renal disease, salicylate (aspirin) toxicity, toxic alcohol ingestions (methanol, ethylene glycol), lactic acidosis (shock, sepsis, tissue hypoperfusion), severe hyperkalemia, and severe hyperchloremia.

  • Metabolic Alkalosis ($\text{HCO}_3^- > 26\,\text{mEq/L}$):

  • Mechanism: Excessive loss of hydrogen/chloride ions or pathological gain/retention of bicarbonate base.

  • Common Causes: Upper gastrointestinal loss (protracted vomiting, prolonged nasogastric tube suctioning), excessive antacid ingestion, iatrogenic sodium bicarbonate infusions, loop and thiazide diuretic administration, hypokalemia, and contraction alkalosis (hypovolemia).

• Physiological Compensation Dynamics:

  • The body strives for homeostasis: when one regulatory system deviates, the opposing system compensates.

  • Respiratory Compensation: Operated by the lungs; extremely fast, initiating within minutes to hours via changes in alveolar minute ventilation.

  • In metabolic acidosis: Rapid hyperventilation (e.g., Kussmaul respirations in DKA) drops $\text{PaCO}_2$.

  • In metabolic alkalosis: Chemoreceptors trigger hypoventilation, elevating $\text{PaCO}_2$.

  • Renal Compensation: Operated by the kidneys; slow, requiring $24\text{ to }72\,\text{hours}$ to fully alter tubular excretion of hydrogen and reabsorption of $\text{HCO}_3^-$.

  • In respiratory acidosis: Renal tubular cells increase acid excretion and generate new bicarbonate, elevating serum $\text{HCO}_3^-$.

  • In respiratory alkalosis: Renal tubules excrete excess bicarbonate, decreasing serum $\text{HCO}_3^-$.

• High-Yield Clinical Tools and Pearls:

  • Electrolyte Rule of Thumb: "When you take acid, you get high." Hyperkalemia and hyperchloremia correlate with metabolic acidosis (cellular exchange pushes potassium out of cells as hydrogen ions enter). Conversely, hypokalemia and hypochloremia correlate directly with metabolic alkalosis.

  • Serum Anion Gap Calculation:

  • Formula: $\text{Anion Gap} = \text{Na}^+ - (\text{Cl}^- + \text{HCO}_3^-)$

  • Normal Reference Range: $8\text{--}12\,\text{mEq/L}$

  • High Anion Gap ($> 12\,\text{mEq/L}$): Signifies addition of unmeasured endogenous or exogenous fixed acids (MUDPILES: Methanol, Uremia, DKA, Paraldehyde, Isoniazid/Iron, Lactic acidosis, Ethylene glycol, Salicylates).

  • Normal Anion Gap (Hyperchloremic Acidosis): Signifies direct bicarbonate loss (severe diarrhea, enteric fistulas) or massive volume expansion with $\text{0.9\% normal saline}$.

  • Winter's Formula for Metabolic Acidosis:

  • Formula: $\text{Expected PaCO}_2 = (1.5 \times [\text{HCO}_3^-]) + 8 \pm 2$

  • Clinical utility: If the measured $\text{PaCO}_2$ is higher than the calculated range, a concomitant primary respiratory acidosis exists. If measured $\text{PaCO}_2$ is lower than expected, a coexisting primary respiratory alkalosis is present.

Principles of Oxygenation, Gas Exchange, and Non-Invasive Oxygen Delivery

• Mechanisms of Arterial Hypoxemia:

  • Hypoventilation: Reduced total volume of inhaled/exhaled air, respiratory muscle weakness from profound hypophosphatemia or hypomagnesemia, obstructive sleep apnea (OSA), and obesity hypoventilation syndrome.

  • Ventilation/Perfusion ($\text{V/Q}$) Mismatch and Shunting: Pulmonary embolus, dense consolidation/pneumonia, atelectasis, and ARDS.

  • Delivery/Consumption ($\text{DO}_2/\text{VO}_2$) Imbalance: Pathological reductions in cardiac output, distributive shock, and severe anemia.

• Oxygen Delivery Devices, Flow Rates, and Delivered Concentrations:

  • Standard Nasal Cannula:

  • Flow: $1\text{--}6\,\text{L/min}$

  • Delivered $\text{FiO}_2$: $24\%\text{--}46\%$

  • High-Flow Nasal Cannula (HFNC):

  • Flow: Up to $60\,\text{L/min}$

  • Delivered $\text{FiO}_2$: $21\%\text{--}100\%$

  • Clinical mechanisms: Delivers heated and fully humidified oxygen; preserves mucociliary transport; decreases caloric expenditure; flushes dead space; provides positive end-expiratory pressure (PEEP) effect.

  • Simple Face Mask:

  • Flow: $5\text{--}10\,\text{L/min}$

  • Delivered $\text{FiO}_2$: $40\%\text{--}60\%$

  • Face Tent:

  • Flow: $10\text{--}15\,\text{L/min}$

  • Delivered $\text{FiO}_2$: Approximately $40\%$

  • Venturi Mask:

  • Flow: $2\text{--}15\,\text{L/min}$

  • Delivered $\text{FiO}_2$: Precise titrations between $24\%\text{--}60\%$

  • Non-Rebreather Mask (NRB):

  • Flow: $12\text{--}15\,\text{L/min}$

  • Delivered $\text{FiO}_2$: $40\%\text{--}100\%$

• Adventitious Pulmonary Sounds:

  • Crackles (Rales): Discontinuous popping sounds caused by fluid in the alveoli or small airways; seen in congestive heart failure, pulmonary edema, pneumonia, and atelectasis.

  • Wheezes: High-pitched musical whistling caused by high-velocity airflow through narrowed, constricted airways; hallmarks of asthma and reactive airway bronchospasm.

  • Rhonchi: Low-pitched, continuous snoring or rattling sounds caused by secretions rattling in large central bronchi; common in chronic bronchitis and pneumonia; often alters after coughing.

  • Stridor: Harsh, high-pitched, vibrating inspiratory sound produced by critical turbulent flow through an obstructed larynx or extrathoracic trachea (e.g., post-extubation laryngeal edema, foreign body aspiration).

• The Oxyhemoglobin Dissociation Curve:

  • Left Shift ("hoLd onto $O_2$"):

  • Hemoglobin exhibits increased affinity for oxygen; binds readily in the pulmonary capillary beds but resists offloading at peripheral tissues.

  • Triggers: AlkaLosis, Low $\text{CO}_2$ (hypocapnia), Low temperature (hypothermia), and Low $2,3\text{-DPG}$.

  • Right Shift ("Release $O_2$"):

  • Hemoglobin exhibits decreased affinity for oxygen; offloads oxygen easily to metabolically active peripheral tissues.

  • Triggers: Acidosis, HypeRcapnia, FeveR (hyperthermia), and elevated ($\uparrow$) $2,3\text{-DPG}$.

  • Review Application Question: Which of the following causes a shift to the left on the oxyhemoglobin dissociation curve? (A. Fever, B. Acidosis, C. Hypercapnia, D. Hypothermia). Correct Answer: D - Hypothermia.

Capnography, Ventilation Monitoring, and Acid-Base Diagnostics

• End-Tidal Carbon Dioxide ($\text{PEtCO}_2$ / $\text{EtCO}_2$):

  • Normal reference range: $35\text{--}45\,\text{mm Hg}$.

  • Represents the partial pressure of carbon dioxide released at the very end of exhalation.

• Dual Physiological Function:

  • Ventilation Metric:

  • Provides continuous non-invasive verification of ventilation with a graphic alveolar plateau waveform.

  • Essential during moderate or deep procedural sedation, continuous opioid/PCA administration, and neurotrauma/head injuries.

  • Alveolar hypoventilation causes carbon dioxide retention, driving $\text{EtCO}_2$ upward ($\uparrow \text{EtCO}_2$).

  • Alveolar hyperventilation rapidly clears carbon dioxide, driving $\text{EtCO}_2$ downward ($\downarrow \text{EtCO}_2$).

  • Perfusion Metric:

  • In low cardiac output states, pulmonary perfusion drops; carbon dioxide delivery to the lungs falls, causing a widening gradient where arterial $\text{PaCO}_2$ significantly exceeds end-tidal $\text{PEtCO}_2$.

  • Resuscitation benchmark: In cardiac arrest CPR, maintaining $\text{EtCO}_2 > 10\,\text{mm Hg}$ reflects adequate chest compression quality (depth of $2\text{--}2.4\,\text{inches}$ or $5\text{--}6\,\text{cm}$).

  • Return of Spontaneous Circulation (ROSC): A sudden, sustained jump in $\text{EtCO}_2 > 40\,\text{mm Hg}$ is an immediate surrogate indicator of ROSC, reflecting an acute surge in cardiac output and pulmonary blood delivery.

• Carbon Monoxide (CO) Poisoning & Co-Oximetry Diagnostics:

  • Clinical Scenario: Patient presenting lethargic with headache, carboxyhemoglobin level $45\%$, on $100\%\,\text{O}_2$ by mask, showing an $\text{SpO}_2$ reading of $100\%$.

  • Pathophysiology: Carbon monoxide binds hemoglobin with an affinity $200\text{ to }250$ times higher than oxygen, forming carboxyhemoglobin ($\text{COHb}$) and starving tissues of cellular oxygen.

  • Critical Diagnostic Warning: Standard two-wavelength pulse oximeters cannot distinguish carboxyhemoglobin from oxyhemoglobin; an $\text{SpO}_2$ of $100\%$ is falsely reassuring and invalid. An arterial blood gas with direct co-oximetry is required to quantify $\text{COHb}$.

  • Clinical Action: Continue $100\%\,\text{FiO}_2$ without titration until symptoms resolve and $\text{COHb}$ drops below $10\%$.

  • Half-life kinetics of $\text{COHb}$:

  • Room air ($21\%\,\text{FiO}_2$): $4\text{--}6\,\text{hours}$

  • High-flow $100\%\,\text{FiO}_2$: $60\text{--}90\,\text{minutes}$

  • Hyperbaric oxygen therapy ($100\%\,\text{O}_2$ under $2.5\text{--}3\,\text{atmospheres}$): $20\text{--}30\,\text{minutes}$

  • Indications for Hyperbaric Oxygen Therapy: Loss of consciousness, active seizures, severe neurological deficits, ischemic cardiac changes, $\text{COHb} > 25\%$, or $\text{COHb} > 15\%$ in pregnant patients (due to fetal hemoglobin vulnerability).

  • Concomitant Cyanide Poisoning: Smoke inhalation victims from closed-space structural fires should be evaluated for concurrent cyanide toxicity, characterized by severe refractory lactic acidosis; treatment is intravenous hydroxocobalamin.

Acute Respiratory Failure: Type 1 Hypoxic vs. Type 2 Hypercapnic

• Classification Comparison:

  • Type 1 – Hypoxic (Oxygenation) Failure:

  • Primary disturbance: Inadequate alveolar-capillary oxygen transfer.

  • Blood gas profile: $\text{PaO}_2 < 60\,\text{mm Hg}$ on room air, $\text{SpO}_2 < 90\%$.

  • Underlying etiologies: Refractory shunt, severe $\text{V/Q}$ mismatch, diffusion defects, alveolar flooding (pulmonary edema, bacterial pneumonia, severe ARDS).

  • Standard therapy: High-flow oxygen devices, HFNC, and continuous positive airway pressure (CPAP).

  • Type 2 – Hypercapnic (Ventilatory) Failure:

  • Primary disturbance: Respiratory pump fatigue, neurological respiratory drive depression, or excessive respiratory dead space.

  • Blood gas profile: $\text{PaCO}_2 > 45\,\text{mm Hg}$ accompanied by an acute acidemic $\text{pH} < 7.35$.

  • Underlying etiologies: Severe COPD exacerbations, end-stage status asthmaticus, drug-induced respiratory depression (opioid overdose), neuromuscular breakdown (myasthenia gravis, Guillain-Barré).

  • Clinical features: Tachypnea, intercostal/sternocleidomastoid accessory muscle usage, elevated minute ventilation compensating for physiological dead space, progressing to lethargy, somnolence, and obtundation as hypercapnia deepens.

  • Standard therapy: Non-invasive positive pressure ventilation (BiPAP) or invasive endotracheal mechanical ventilation.

• Pneumonia in Critical Care:

  • Community-Acquired Pneumonia (CAP): Most common subtype, contracted outside hospital settings; approximately $100$ causative microbial pathogens identified.

  • Hospital-Acquired Pneumonia (HAP): Infectious pulmonary parenchymal inflammation developing $48\,\text{hours}$ or more after inpatient hospital admission.

  • Ventilator-Associated Pneumonia (VAP): Pulmonary parenchymal infection arising $48\text{--}72\,\text{hours}$ following endotracheal intubation. Carries a crude mortality exceeding $25\%$. Hallmark signs: new or persistent fever, leukocytosis, purulent endobronchial secretions, and progressive radiographic infiltrates.

  • Diagnostic workup: Blood cultures prior to antibiotic initiation, deep endotracheal aspirate or bronchoalveolar lavage (BAL) sputum cultures, serial CBC, and chest imaging.

  • Comprehensive nursing bundle: Semirecumbent positioning ($\text{HOB } 30\text{--}45^\circ$), chlorhexidine oral hygiene, subglottic secretion drainage, early physical mobilization, and targeted antibiotic therapy.

• Non-Invasive Positive Pressure Ventilation (NIPPV) Modalities:

  • Continuous Positive Airway Pressure (CPAP):

  • Target: Hypoxemia (Type 1 Failure).

  • Settings: Constant continuous airway pressure throughout both inspiration and expiration, typically set at $5\text{--}10\,\text{cm H}_2\text{O}$.

  • Action: Splints open terminal airways during exhalation, increases Functional Residual Capacity (FRC), recruits microatelectatic alveolar units, but does not augment tidal volume.

  • Bi-level Positive Airway Pressure (BiPAP):

  • Target: Hypercapnia (Type 2 Failure).

  • Settings: Cycles between two distinct pressure levels: Inspiratory Positive Airway Pressure (IPAP) and Expiratory Positive Airway Pressure (EPAP).

  • Typical starting parameters: IPAP $10\,\text{cm H}_2\text{O}$, EPAP $5\,\text{cm H}_2\text{O}$.

  • Action: The pressure delta (IPAP minus EPAP) functions as pressure support, directly augmenting tidal volume, reducing work of breathing, and clearing carbon dioxide, while EPAP recruits alveoli.

• Complication Prevention: Critical risk of full-thickness skin pressure injury over the nasal bridge, forehead, cheeks, and chin. Prophylactic hydrocolloid or silicone barrier dressings must be applied early over high-contact pressure points.

  • Sleep-Disordered Breathing:

• Obstructive Sleep Apnea (OSA): Physical upper airway collapse and occlusion driven by redundant pharyngeal tissue, neck/abdominal adiposity, micrognathia, or hypertrophic tonsillar tissue. Aggravated by supine sleeping. Managed with lifestyle weight loss, surgical tonsillectomy, nocturnal CPAP, or BiPAP if chronic daytime hypercapnia develops.

• Central Sleep Apnea (CSA): Transient cessation of neural ventilatory drive originated within the pontomedullary respiratory center of the brainstem; associated with advanced heart failure (Cheyne-Stokes breathing) and chronic high-dose opioid use. Managed with CPAP or Adaptive Servo-Ventilation (ASV), which monitors real-time breathing mechanics and auto-adjusts pressure profiles to eliminate apneic episodes.

Obstructive Pulmonary Diseases: Status Asthmaticus and COPD Exacerbation

• Acute Severe Asthma and Status Asthmaticus:

  • Pathophysiology: Chronic airway inflammation, marked bronchial hyperreactivity, profound bronchospasm, and thick mucus hypersecretion with extensive luminal plugging.

  • Dynamic Pulmonary Mechanics: Profound airway resistance leads to incomplete expiratory emptying, air trapping, hyperinflation, and the generation of intrinsic PEEP (auto-PEEP), which raises intrathoracic pressures and limits venous return.

  • Review Practice Vignette: An asthma exacerbation exhibits which physiological changes? (A. Decreased vital capacity, decreased peak inspiratory flow, decreased peak expiratory flow rate; B. Increased vital capacity, decreased peak inspiratory flow, increased peak expiratory flow rate; C. Decreased vital capacity, increased peak inspiratory flow, increased forced expiratory volume; D. Increased vital capacity, decreased peak inspiratory flow, decreased forced expiratory volume). Correct Answer: A - Decreased vital capacity, decreased peak inspiratory flow, and decreased peak expiratory flow rate.

  • Two-Phase Pathological Progression:

  • Phase 1 (Early Bronchospastic Phase): Degranulation of mast cells and basophils releasing histamine, leukotrienes, and prostaglandins, causing immediate bronchial smooth muscle spasm, vascular leakage, and hypersecretion.

  • Phase 2 (Late Inflammatory Phase): Peak onset $6\text{ to }12\,\text{hours}$ post-exposure, marked by eosinophil and neutrophil infiltration, mucosal edema, cellular sloughing, severe mucus plugging, and worsening airflow obstruction.

  • Clinical Trajectory and Warning Signs:

  • Early auscultation reveals high-pitched inspiratory and expiratory wheezes with tachypnea. Wheezing indicates preserved gas movement.

  • Late, decompensating auscultation reveals diminished or entirely "silent chest" breath sounds, representing an emergency.

  • ABG Evolution: Hyperventilation initially creates respiratory alkalosis ($\downarrow \text{PaCO}_2$). As respiratory muscles exhaust, $\text{PaCO}_2$ normalizes; a "normal" $\text{PaCO}_2\ (35\text{--}45\,\text{mm Hg})$ in an acutely breathless asthmatic is an ominous sign of imminent arrest. Further tiring produces severe respiratory acidosis ($\uparrow \text{PaCO}_2$).

  • Pharmacological Management Protocol:

  • First-line: Short-Acting Beta-2 Agonist (SABA) bronchodilators (e.g., Albuterol). Mechanism: Stimulates bronchial beta-2 adrenergic receptors, relaxing smooth muscle. Dose: $2.5\,\text{mg}$ intermittent nebulization or continuous nebulization at $5\text{--}15\,\text{mg/hour}$. Onset: $< 5\,\text{minutes}$; duration $2\text{--}5\,\text{hours}$.

  • Second-line / Add-on: Inhaled short-acting anticholinergic (Ipratropium bromide / Atrovent) to inhibit muscarinic bronchoconstriction.

  • Systemic Corticosteroids: Administer pulse-dose IV methylprednisolone or oral prednisone ($5\text{--}7\,\text{days}$, no taper necessary for short courses). Decreases airway edema and suppresses inflammatory recurrence. Peak clinical onset requires approximately $12\,\text{hours}$.

  • Intravenous Magnesium Sulfate: $1\text{--}2\,\text{grams}$ infused over $1\,\text{hour}$; functions as a direct physiological smooth muscle calcium-channel blocker, causing bronchodilation.

  • Heliox (Helium-Oxygen mixture): Administered at ratios of $70:30$ or $60:40$. Lower density than atmospheric air, converting turbulent airway flow to laminar flow, reducing airway resistance, and easing the work of breathing.

  • Intramuscular Epinephrine: Non-selective alpha- and beta-agonist; provides emergency rescue bronchodilation and mucosal vasoconstriction.

  • Aggressive Hydration: Essential to correct large insensible fluid losses from tachypnea and thin tenacious bronchial secretions.

  • Albuterol Side Effect Profile:

  • Tachycardia and peripheral tremors (stimulation of beta-2 and off-target beta-1 receptors).

  • Hyperglycemia (enhanced hepatic glycogenolysis).

  • Hypokalemia (drives extracellular potassium into cells via activation of the sodium-potassium ATPase pump).

  • Hypomagnesemia and hypophosphatemia.

  • Emergency Intubation Criteria: Severe lethargy, stupor, gasping respirations, paradoxical abdominal breathing, refractory severe hypercapnia/acidosis, or loss of consciousness.

• Chronic Obstructive Pulmonary Disease (COPD):

  • Spectrum includes chronic bronchitis and emphysema, frequently coexisting with dynamic airway hyperreactivity.

  • Emphysema ("Pink Puffers"):

  • Pathophysiology: Protease-mediated destruction of terminal alveolar walls, permanent airspace enlargement, and loss of elastic recoil, creating expiratory dynamic airway collapse.

  • Presentation: Thin, cachectic build; barrel-shaped chest (elevated AP diameter); pursed-lip breathing; accessory muscle use; pink/rosy complexion; minimal mucoid sputum.

  • Radiography: Hyperinflated lung fields, flattened diaphragmatic domes, widened intercostal spaces, and apical bullae.

  • Chronic Bronchitis ("Blue Bloaters"):

  • Pathophysiology: Chronic bronchial inflammation with goblet cell hyperplasia, excessive thick mucus secretion, and impaired mucociliary transport.

  • Presentation: Chronic, productive cough for at least $3\,\text{consecutive months}$ in $2\,\text{consecutive years}$; overweight, plethoric, cyanotic; prominent peripheral edema from right ventricular failure.

  • Radiography: Prominent bronchovascular markings with normal lung size and diaphragmatic contour.

  • Pulmonary Function Testing (Spirometry): Post-bronchodilator $\text{FEV}_1/\text{FVC} < 0.70$ ($< 70\%$

  • COPD Exacerbation Management:

  • Inhaled SABA (Albuterol) plus SAMA (Ipratropium).

  • Short-course systemic corticosteroids ($5\text{--}10\,\text{days}$, Number Needed to Treat [NNT] = $10$).

  • Oxygen Therapy Target: Titrate to an $\text{SpO}_2$ goal of $88\%\text{--}92\%$. Uncontrolled delivery of high $\text{FiO}_2$ extinguishes hypoxic vasoconstriction, increases dead-space ventilation (Haldane effect), and suppresses the hypoxic ventilatory drive, leading to acute hypercapnic coma.

  • Mechanical Ventilation Setting Adjustments: Lower mandatory rates, low tidal volumes ($6\text{--}8\,\text{mL/kg}$ PBW), and shortened inspiratory times ($0.6\text{--}0.8\,\text{seconds}$, compared to normal $0.8\text{--}2.0\,\text{seconds}$) with prolonged expiratory pauses to achieve an $\text{I:E}$ ratio of $1:3$ to $1:4$ to prevent auto-PEEP.

  • Surgical Interventions (VATS / LVRS): Video-Assisted Thoracoscopic Surgery (VATS) lung volume reduction surgery (LVRS) excises the most non-functioning, hyperinflated emphysematous lung regions (predominantly upper lobes), allowing preserved pulmonary segments to expand, restoring diaphragmatic mechanics, and improving exercise tolerance.

Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation

• Pathogenesis and Cascade:

  • Triggered by direct pulmonary insult (bacterial/viral pneumonia, gastric aspiration, pulmonary contusion) or indirect systemic insult (sepsis, severe pancreatitis, multiple trauma, massive transfusion-related acute lung injury [TRALI]).

  • Pathological cascade: Systemic inflammation causes leukocyte recruitment and sequestration within pulmonary capillaries; release of inflammatory cytokines (TNF, interleukins), proteases, and reactive oxygen species causes diffuse alveolar-capillary membrane destruction.

  • Capillary endothelial leak leads to non-cardiogenic pulmonary edema, flooding interstitial spaces and alveoli.

  • Alveolar type II pneumocyte damage obliterates surfactant production, increasing surface tension, causing widespread microatelectasis, severe loss of compliance ("stiff lungs"), and a massive anatomical intrapulmonary shunt (venous blood traverses unventilated alveoli without oxygenation).

• Diagnostic Criteria (The Berlin Definition):

  • Timing: Acute onset within $1\,\text{week}$ of a known clinical insult or new/worsening respiratory symptoms.

  • Chest Imaging: Bilateral patchy opacities/infiltrates on chest radiography or CT scan not fully explained by effusions, lobar collapse, or pulmonary nodules ("white-out").

  • Origin of Edema: Non-cardiogenic; pulmonary artery occlusion pressure (PAOP / wedge) is normal ($\le 18\,\text{mm Hg}$) with no evidence of left-sided heart failure or fluid overload.

  • Oxygenation Deficit ($\text{P/F}$ Ratio = $\text{PaO}_2 \div \text{FiO}_2$):

  • Mild ARDS: $\text{P/F } 201\text{--}300\,\text{mm Hg}$ on PEEP/CPAP $\ge 5\,\text{cm H}_2\text{O}$ (mortality $\approx 27\%$

  • Moderate ARDS: $\text{P/F } 101\text{--}200\,\text{mm Hg}$ on PEEP $\ge 5\,\text{cm H}_2\text{O}$ (mortality $\approx 32\%$

  • Severe ARDS: $\text{P/F } \le 100\,\text{mm Hg}$ on PEEP $\ge 5\,\text{cm H}_2\text{O}$ (mortality $\approx 45\%$

• Evidence-Based Management (Lung-Protective Ventilation):

  • Low Tidal Volume Ventilation: Initiate at $6\,\text{mL/kg}$ of Predicted Body Weight (PBW); range $4\text{--}8\,\text{mL/kg}$ PBW. Minimizes alveolar overdistention (volutrauma).

  • End-Inspiratory Plateau Pressure Limit: Maintain plateau pressure ($\text{P}_{\text{plat}}$) strictly below $30\,\text{cm H}_2\text{O}$. If $\text{P}_{\text{plat}} > 30\,\text{cm H}_2\text{O}$, step down the tidal volume (to $5\,\text{mL/kg}$, then $4\,\text{mL/kg}$ PBW).

  • PEEP Titration: Higher levels of PEEP ($10\text{--}24\,\text{cm H}_2\text{O}$) act as internal stents to recruit collapsed alveoli, prevent cyclic end-expiratory collapse (atelectrauma), and improve refractory hypoxemia. Hemodynamic warning: High PEEP increases intrathoracic pressure, decreases right ventricular venous return, reduces cardiac output, and induces systemic hypotension. Manage hypotension with vasopressors and judicious fluid titration, avoiding PEEP reduction when possible.

  • Permissive Hypercapnia: Allow $\text{PaCO}_2$ to rise ($50\text{--}70\,\text{mm Hg}$) to accommodate lung-protective small tidal volumes, provided arterial $\text{pH}$ remains above $7.20\text{--}7.25$.

  • Prone Positioning: Indicated for moderate-to-severe ARDS ($\text{P/F} < 150\,\text{mm Hg}$). Initiated early for a minimum of $16\text{--}20\,\text{hours/day}$. Shifts ventral lung tissue dependent, reduces dorsal alveolar compression by the heart and abdominal viscera, improves drainage of dorsal secretions, and enhances overall $\text{V/Q}$ matching.

  • Neuromuscular Blockade (Paralytics): Continuous infusion of cisatracurium or rocuronium within the first $48\,\text{hours}$ of severe ARDS eliminates patient-ventilator dyssynchrony, reduces transpulmonary pressure swings, decreases barotrauma, and lowers systemic inflammatory markers.

  • Inhaled Pulmonary Vasodilators: Inhaled nitric oxide (iNO) or inhaled epoprostenol (Flolan) selectively vasodilate pulmonary capillary vessels in ventilated alveoli, improving $\text{V/Q}$ matching and decreasing pulmonary vascular resistance without inducing systemic hypotension.

  • Veno-Venous Extracorporeal Membrane Oxygenation (VV ECMO): Ultimate rescue modality for refractory hypoxemic respiratory failure where lung-protective mechanical ventilation is unable to sustain cellular oxygenation.

Pulmonary Vascular Disorders: Pulmonary Embolism, Pulmonary Hypertension, and Hemorrhage

• Acute Pulmonary Embolism (PE):

  • Pathophysiology: Physical obstruction of the pulmonary arterial bed by a detached thromboembolus (most commonly derived from lower extremity deep veins in $70\%$ of cases), fat droplets, or air.

  • The vascular occlusion creates alveolar dead-space ventilation ($\text{V/Q}$ mismatch where areas are ventilated but unperfused), releases vasoconstrictive humoral mediators, elevates pulmonary vascular resistance (PVR), and causes acute right ventricular pressure overload.

  • Signs & Symptoms: Tachypnea ($96\%$

  • Fat Embolism Syndrome (FES):

  • Clinical Scenario: Sudden restlessness, tachypnea ($\text{RR } 34$

  • Onset: Typically manifests $24\text{ to }72\,\text{hours}$ following traumatic injury.

  • Classic Diagnostic Triad: Respiratory distress (hypoxemia, tachypnea), neurological changes (confusion, agitation, altered LOC), and a transient petechial rash distribution (chest, axillae, subconjunctival spaces).

  • Therapy: Primarily supportive care (supplemental oxygen, mechanical ventilation, fluid resuscitation, and early operative fracture stabilization). Anticoagulants and fibrinolytics are ineffective against physical fat globules and are contraindicated for isolated fat embolism.

  • Diagnostic Evaluation for PE:

  • Computed Tomography Pulmonary Angiography (CTPA): Diagnostic gold standard ($83\%$ sensitivity, $96\%$ specificity, and $96\%$ positive predictive value). Visualizes filling defects in the pulmonary arterial tree.

  • Ventilation/Perfusion (V/Q) Scan: Utilized in patients with severe renal failure, contrast allergies, or pregnancy; diagnostic in only $25\%\text{--}30\%$ of cases.

  • D-Dimer Assay: Highly sensitive ($> 95\%$

  • 12-Lead Electrocardiogram: Frequently displays sinus tachycardia. Massive PE produces right heart strain manifestations: the classic $S_1 Q_3 T_3$ pattern (deep S-wave in lead I, prominent Q-wave in lead III, inverted T-wave in lead III), new right bundle branch block (RBBB), right-axis deviation, and T-wave inversions across precordial leads $V_1\text{--}V_4$.

• Therapeutic Protocols:

  • Anticoagulation: Weight-based Unfractionated Heparin (UFH) targeting an aPTT of $50\text{--}80\,\text{seconds}$, Low Molecular Weight Heparin (Enoxaparin $1\,\text{mg/kg}$ subcutaneously every $12\,\text{hours}$, renally adjusted), Fondaparinux, or Direct Oral Anticoagulants (DOACs). Warfarin initiated concurrently with heparin, bridging until INR reaches $2.0\text{--}3.0$.

  • Hemodynamically Unstable (Massive) PE ($\text{SBP} < 90\,\text{mm Hg}$ or cardiac arrest): Systemic fibrinolytic therapy using recombinant tissue plasminogen activator (Alteplase $100\,\text{mg}$ IV infusion over $2\,\text{hours}$) or Tenecteplase. Carries a $12\%$ major bleeding and $1\%$ intracranial hemorrhage risk. Mechanical pulmonary thrombectomy (FlowTriever/Inari) or catheter-directed ultrasound-assisted thrombolysis (EKOS) are alternatives when systemic lysis is contraindicated.

  • Inferior Vena Cava (IVC) Filters: Indicated for proven DVT/PE with absolute contraindications to anticoagulation, recurrent embolism despite therapeutic anticoagulation, or free-floating iliofemoral thrombi.

  • Air Embolism:

• Venous Air Embolism: Air enters systemic venous circulation through central venous catheter manipulation, insertion, or accidental line detachment. Air lodges in the right ventricular outflow tract, impeding pulmonary flow.

  • Interventions: Immediately position patient in left lateral decubitus Trendelenburg position (traps the air bubble in the right ventricular apex, preventing pulmonary arterial outflow blockage); administer $100\%\,\text{FiO}_2$ to accelerate nitrogen washout and bubble reabsorption; consider hyperbaric oxygen therapy.

• Arterial Air Embolism: Air enters arterial vasculature during cardiothoracic or vascular procedures; as little as $2\,\text{mL}$ in cerebral circulation can cause fatal ischemic stroke; $0.5\,\text{mL}$ in coronary arteries can trigger fatal myocardial infarction.

  • Pulmonary Arterial Hypertension (PAH):

• Pathophysiology: Chronic sustained elevation of pulmonary vascular resistance leading to right ventricular hypertrophy, dilation, and eventual right ventricular pump failure (cor pulmonale).

• Diagnostic Benchmark: Mean Pulmonary Artery Pressure ($\text{mPAP}$) $\ge 20\,\text{mm Hg}$ measured at rest via right heart catheterization.

• Pharmacological Strategies:

  • Oral agents for maintenance: Phosphodiesterase-5 inhibitors (Sildenafil), endothelin receptor antagonists (Bosentan), and oral calcium-channel blockers.

  • Rapid progression / advanced decompensation: Continuous intravenous or subcutaneous prostacyclin analogues (Epoprostenol / Flolan, Treprostinil / Remodulin) to induce direct pulmonary vascular smooth muscle relaxation and reverse vascular remodeling.

  • Pulmonary Hemorrhage:

• Underlying causes: Bronchiectasis, cavitary tuberculosis, bronchogenic carcinomas, fungal mycetomas, and invasive pulmonary trauma.

• Critical Nursing Action: Prioritize airway clearance, endotracheal intubation (often with larger tubes, size $\ge 8.0\,\text{mm}$, to facilitate therapeutic bronchoscopy), and position the patient with the bleeding lung DOWN (lateral decubitus) to prevent gravitational aspiration of blood into the non-bleeding lung. Correct coagulopathies and administer intravenous tranexamic acid (TXA) as prescribed.

Pleural Space Pathologies, Thoracic Trauma, and Chest Tube Drainage Systems

• Pneumothorax Classification and Management:

  • Closed (Spontaneous) Pneumothorax: Pleural disruption occurs from within (rupture of subpleural apical blebs, emphysematous bullae, or high alveolar airway pressures from mechanical ventilation).

  • Open (Communicating) Pneumothorax: Penetrating thoracic wall trauma creating a "sucking chest wound" where air moves freely across the chest wall defect. Managed immediately with a three-sided occlusive dressing (creates a one-way flutter valve) followed by tube thoracostomy.

  • Tension Pneumothorax:

  • Life-threatening emergency: Pleural tear acts as a one-way valve, allowing atmospheric air into the intrapleural space during inspiration but preventing its egress during expiration.

  • Intrathoracic pressure builds rapidly, causing ipsilateral lung collapse, shifting the mediastinum and trachea toward the unaffected side, compressing the superior and inferior vena cava, impairing right atrial filling, collapsing cardiac output, and progressing to pulseless electrical activity (PEA) arrest.

  • Assessment Findings: Hyperresonance to percussion over the affected hemithorax, absent breath sounds on the affected side, tracheal deviation away from the affected side, jugular venous distention (JVD), severe tachycardia, and profound hypotension.

  • Emergency Decompression: Do not delay treatment for radiographic confirmation. Perform immediate needle thoracostomy using a large-bore ($14\text{--}16\,\text{gauge}$) angiocatheter at either the $2\text{nd}$ intercostal space at the midclavicular line or the $4\text{th}\text{--}5\text{th}$ intercostal space along the anterior-to-midaxillary line, followed by definitive chest tube insertion.

• Hemothorax:

  • Blood collection in the intrapleural space; causes lung compression, alveolar collapse, and acute hemorrhagic shock.

  • Assessment: Dullness to percussion, absent breath sounds over the affected hemithorax, tracheal deviation away from the affected side (if massive), and flat/collapsed neck veins (reflecting hypovolemia, contrasting with JVD in tension pneumothorax).

  • Diagnostic/Interventional Cutoffs: Drainage of $> 400\,\text{mL}$ is clinically significant. Massive hemothorax is defined as an immediate initial output of $\ge 1500\,\text{mL}$ upon chest tube placement, or persistent bleeding $> 200\,\text{mL/hour}$ for $2\text{ to }4\,\text{consecutive hours}$, representing an absolute indication for emergency exploratory thoracotomy.

• Differential Chest Assessment by Clinical Condition:

  • Tension Pneumothorax: Percussion = Hyperresonant; Breath Sounds = Absent; Trachea = Shifts toward unaffected side; Neck Veins = Distended.

  • Massive Hemothorax: Percussion = Dull; Breath Sounds = Absent; Trachea = Shifts toward unaffected side; Neck Veins = Flat/collapsed.

  • Status Asthmaticus (Early): Percussion = Hyperresonant (air trapping); Breath Sounds = Expiratory/inspiratory wheezing; Trachea = Midline.

  • Status Asthmaticus (Late Exhaustion): Percussion = Hyperresonant; Breath Sounds = Diminished to silent; Trachea = Midline.

  • ARDS: Percussion = Dull over consolidated bases; Breath Sounds = Bilateral diffuse crackles; Trachea = Midline.

• Chest Tube Drainage Systems:

  • Pleural vs. Mediastinal Tubes:

  • Pleural chest tubes are inserted into the pleural cavity to evacuate air, blood, or effusions, with the primary therapeutic goal of restoring physiological negative intrapleural pressure and re-expanding collapsed lung parenchyma.

  • Mediastinal chest tubes are placed directly into the mediastinal space following cardiac surgery; their exclusive role is to evacuate blood and pericardial fluid to prevent acute cardiac tamponade; they do not re-expand lung tissue.

  • The Three-Chamber Unit:

  • Chamber 1 (Drainage Collection): Collects and measures fluid output directly from the patient.

  • Chamber 2 (Water Seal / Air Leak Detector): Filled with sterile water to the $2\,\text{cm}$ mark. Serves as a one-way valve allowing air to escape from the pleura while preventing atmospheric air from re-entering.

  • Chamber 3 (Suction Control Chamber): Regulates applied negative suction (typically $-10\text{ to }-40\,\text{cm H}_2\text{O}$, standardly set at $-20\,\text{cm H}_2\text{O}$). In wet systems, gentle continuous bubbling indicates proper suction regulation.

  • Tidaling Dynamics:

  • Normal fluctuation of the water column in the water-seal chamber corresponding to respiration.

  • In a spontaneously breathing patient: The fluid column rises on inspiration (negative pleural pressure draws fluid up) and falls on expiration.

  • In a positive-pressure mechanically ventilated patient: The pattern reverses; the water level falls on inspiration (positive pressure pushes fluid down) and rises on expiration.

  • Cessation of tidaling signifies either complete lung re-expansion and resolution of the pleural defect, or mechanical obstruction of the tubing (fibrin clot or kink).

  • Air Leak Assessment & Troubleshooting:

  • Intermittent bubbling in the water-seal chamber during exhalation or coughing is normal in the presence of an active pneumothorax and diminishes as the lung heals.

  • Continuous bubbling across both phases of respiration indicates an active air leak.

  • Troubleshooting an air leak: Systematically clamp the tubing momentarily with padded forceps starting at the thoracic insertion site. If bubbling stops immediately upon clamping at the insertion dressing, the leak originates from the patient's pleura or the insertion site. If bubbling persists when clamped downstream, the leak is located within the external tubing connections or the drainage canister itself.

  • Safety Rules: Never clamp a bubbling chest tube during transport or routine care, as this blocks air egress and can convert an unresolved pneumothorax into a tension pneumothorax.

• Thoracic Trauma & Rib Fractures:

  • Rib Fractures: Fractures of ribs $4\text{--}8$ are most common. Fractures of lower ribs ($9\text{--}12$) carry high risk for laceration of the spleen (left), liver (right), or diaphragmatic tear. Management relies on aggressive multi-modal analgesia (thoracic epidural catheters, intercostal nerve blocks) to allow deep breathing and aggressive pulmonary toileting to prevent secondary atelectasis and pneumonia.

  • Pulmonary Contusion: Parenchymal lung injury involving ruptured alveolar-capillary networks, localized edema, and intrapulmonary hemorrhage developing over $24\text{ to }72\,\text{hours}$ post-blunt trauma. Diagnostic hallmark on CT/X-ray: patchy parenchymal opacities beneath the contused thoracic wall. Clinical signs: hemoptysis (pink frothy sputum), tachypnea, hypoxemia, and decreased lung compliance. Avoid over-resuscitation with intravenous fluids, which worsens parenchymal edema; severe cases require lung-protective mechanical ventilation identical to ARDS protocols.

Thoracic Surgical Interventions and Postoperative Critical Care

• Surgical Resection Types:

  • Wedge Resection: Removal of a small, localized triangular segment of peripheral lung parenchyma, preserving surrounding lobar architecture.

  • Lobectomy: Complete surgical excision of an entire anatomical lung lobe (right upper, middle, lower; left upper, lower); the most common surgical intervention for localized resectable non-small cell lung cancer.

  • Pneumonectomy: Total surgical excision of an entire single lung, along with pulmonary vascular dissection and mediastinal lymph node harvesting.

• Postoperative Nursing Management & Hemodynamics:

  • Strict Fluid Restriction Protocol: Critical priority in post-thoracic surgery patients. Pulmonary vascular capacity is acutely reduced (by $> 50\%$ in a right pneumonectomy). Volume overload readily precipitates fatal non-cardiogenic pulmonary edema in the remaining lung. Total fluid administration within the first $24\,\text{hours}$ should generally be maintained strictly below $20\,\text{mL/kg}$.

  • Transfusion Thresholds: Conservative transfusion protocols apply; red blood cell transfusions are withheld unless hemoglobin drops below $7.0\,\text{g/dL}$ accompanied by clinical signs of hypoperfusion.

  • Post-Pneumonectomy Positioning: Position the patient with the operative lung DOWN and the intact, non-operative lung UP in the lateral decubitus position. This facilitates fluid accumulation in the empty hemithorax and maximizes perfusion and ventilation matching to the healthy dependent lung.

  • Post-Pneumonectomy Chest Tube Safety Rule: A chest tube placed in a pneumonectomy cavity must NEVER be connected to suction. It is maintained exclusively on water seal or clamped and balanced. Negative suction shifts the mediastinum toward the operative side, compromising venous return and causing hemodynamic collapse.

  • Postoperative Dysrhythmias: Atrial fibrillation occurs in up to $30\%$ of post-thoracic surgery patients due to right atrial irritation and elevated pulmonary pressures. In pneumonectomy patients, Amiodarone is avoided due to its risk of acute pulmonary toxicity and pneumonitis. Rate control is managed using intravenous beta-blockers or non-dihydropyridine calcium channel blockers (Diltiazem).

Advanced Airway Management, Endotracheal Intubation, and Tracheostomy Care

• The 8 P's of Rapid Sequence Intubation (RSI):

  1. Plan: Establish primary, secondary, and surgical rescue airway backup strategies.

  2. Preparation: Assemble and function-check all pharmacologic agents, laryngoscopes, video blades, stylets, suction, and capnography detectors.

  3. Positioning: Optimize external laryngeal alignment. Place the patient in the "sniffing position" (cervical spine flexion with atlanto-occipital joint extension).

  4. Preoxygenation: Administer high-fractional oxygen ($100\%\,\text{FiO}_2$) via tight-seal non-rebreather mask or CPAP for $3\text{ to }5\,\text{minutes}$ to replace alveolar nitrogen and extend the safe apnea period.

  5. Pretreatment: Administer hemodynamic medications (vasopressors, fluids) to blunt acute hypotensive responses upon induction.

  6. Paralysis and Induction: Rapid, synchronized administration of an induction sedative (Etomidate, Propofol, Ketamine) followed immediately by a neuromuscular blocker (Succinylcholine or Rocuronium).

  7. Placement with Proof: Direct or video laryngoscopy visualization passing the endotracheal tube through the vocal cords, followed by immediate diagnostic verification.

  8. Postintubation Management: Secure the tube, connect mechanical ventilation, obtain post-procedure chest radiograph, and initiate continuous analgosedation.

• Endotracheal Tube Mechanics & Depth Standards:

  • Standard Sizes (Internal Diameter [ID]): Size $7.5\,\text{mm}$ standard for adults; size $7.0\,\text{mm}$ for smaller females; size $8.0\,\text{mm}$ for larger males. Smaller tube diameters exponentially elevate airway resistance ($\text{Poiseuille's Law}$).

  • Cuff Pressure Maintenance: Inflate endotracheal cuff to precisely $20\text{--}30\,\text{cm H}_2\text{O}$. Cuff pressures exceeding $30\,\text{cm H}_2\text{O}$ cause mucosal ischemia and tracheal necrosis; pressures below $20\,\text{cm H}_2\text{O}$ allow aspiration of subglottic secretions and loss of delivered tidal volume.

  • Radiographic Positioning: The distal radiopaque endotracheal tip must rest precisely $3\text{ to }4\,\text{cm}$ superior to the carina at the level of the aortic arch / $T_2\text{--}T_4$ vertebrae.

• Placement Verification:

  • Auscultation: Bilateral breath sounds over mid-axillary lines, accompanied by absence of epigastric sounds.

  • Colorimetric Carbon Dioxide Detection: Disposable detector (e.g., Easy Cap II) attached to ETT hub; chemical changes color from purple to yellow in the presence of expired carbon dioxide.

  • Continuous Waveform Capnography: The clinical gold standard for continuous endotracheal confirmation; produces a sustained rectangular plateau over multiple breaths.

• Tracheostomy Nursing Care:

  • Indicated for prolonged ventilator dependence ($> 10\text{--}14\,\text{days}$) or anatomical upper airway obstruction.

  • Emergency Bedside Safety Requirement: A replacement tracheostomy tube of the same size, a backup tracheostomy tube one size smaller, and the matched obturator must remain at the bedside at all times.

  • Cleaning Protocols: Avoid concentrated hydrogen peroxide on mucosal surfaces (causes chemical burn and tissue granulation); clean with sterile normal saline.

  • Speaking Valves (e.g., Passy-Muir): The tracheostomy cuff must be completely deflated prior to speaking valve placement. Leaving the cuff inflated with a one-way speaking valve obstructs exhalation, causing immediate air trapping, barotrauma, and suffocation.

Mechanical Ventilation Principles, Modes, Alarms, and Critical Care Sedation

• Physiological Determinants of Lung Compliance:

  • Compliance Concept: Compliance is the measure of lung tissue distensibility (stretchability). Reduced compliance increases the muscular work of breathing.

  • Static Compliance ($C_{\text{stat}}$): Reflects the elastic recoil of the lung parenchyma and chest wall. Measured during an end-inspiratory hold pause when airflow has ceased. Calculated as: $C_{\text{stat}} = \frac{\text{Tidal Volume}}{\text{Plateau Pressure} - \text{PEEP}}$. Decreased in ARDS, dense pneumonia, pulmonary contusion, and chest wall deformities.

  • Dynamic Compliance ($C_{\text{dyn}}$): Reflects compliance during active gas delivery and is governed by airway resistance. Calculated as: $C_{\text{dyn}} = \frac{\text{Tidal Volume}}{\text{Peak Inspiratory Pressure} - \text{PEEP}}$. Decreased in asthma exacerbation, bronchospasm, endobronchial secretions, and kinked/bitten endotracheal tubes.

  • Diagnostic Clinical Pearl: An elevated Peak Inspiratory Pressure (PIP) with a normal Plateau Pressure ($\text{P}_{\text{plat}}$) indicates an isolated airway resistance problem (secretions, bronchospasm, tube kinking). An elevated PIP combined with an elevated $\text{P}_{\text{plat}}$ indicates an intrinsic lung compliance problem (pneumothorax, ARDS, pulmonary edema, abdominal compartment syndrome).

• Mechanical Ventilation Modes:

  • Volume-Targeted Modes (Assist/Control [A/C-VC], Volume CMV): Delivers a preset mandatory tidal volume with every delivered breath. If the patient triggers a spontaneous breath, the ventilator delivers the full preset volume. Lowers work of breathing, but variable airway pressures can cause barotrauma if lung compliance falls.

  • Pressure-Targeted Modes (Pressure Control [PCV]): Delivers gas until a preset pressure limit is reached, maintained across a set inspiratory time. Tidal volume varies with changing lung compliance. Limits airway pressure spikes.

  • Pressure Support Ventilation (PSV): A spontaneous breathing mode where the patient initiates every breath, governing rate, flow, and inspiratory duration. The ventilator delivers a preset positive pressure during inspiration to overcome endotracheal tube resistance. Used during weaning trials; pressure is adjusted to achieve a tidal volume of $6\text{--}8\,\text{mL/kg}$.

• Ventilator Adjustments for Arterial Blood Gas Abnormalities:

  • To manage $\text{PaO}_2$: Titrate $\text{FiO}_2$ and PEEP.

  • To manage $\text{PaCO}_2$: Titrate minute ventilation (Respiratory Rate $\times$ Tidal Volume). If $\text{PaCO}_2$ is elevated and $\text{pH}$ is acidotic, increase the mandatory respiratory rate or tidal volume. If $\text{PaCO}_2$ is low and $\text{pH}$ is alkalotic, reduce the mandatory respiratory rate.

• Ventilator Circuit Alarms and Troubleshooting:

  • High-Pressure Alarm: Triggered when circuit pressure exceeds preset limits. Causes: Bronchospasm, secretions, patient biting the tube, ventilator dyssynchrony, tubing water condensation, kinked circuit, dynamic hyperinflation (auto-PEEP), tension pneumothorax, or declining compliance.

  • Low-Pressure / Low Minute Ventilation Alarm: Triggered when circuit pressure fails to reach threshold or minute volume drops. Causes: Disconnection from the ETT, loose tubing humidification adapters, deflated or ruptured endotracheal cuff, or large chest tube air leak.

• Ventilator-Associated Event (VAE) Prevention Bundle:

  • Elevation of head of bed ($30\text{--}45^\circ$

  • Routine oral hygiene using $0.12\%$ chlorhexidine oral rinse.

  • Daily Spontaneous Awakening Trials (SAT) and Spontaneous Breathing Trials (SBT).

  • Early physical mobilization and ambulation.

  • Venous thromboembolism (DVT) and gastrointestinal ulcer prophylaxis.

  • Conservative fluid management to avoid pulmonary extravasation.

• Critical Care Sedation Pharmacology:

  • Propofol (Diprivan): Sedative, amnesic, and hypnotic agent with rapid onset and an elimination half-life of $4\text{--}8\,\text{minutes}$. Dosage: Continuous IV infusion at $5\text{--}50\,\text{mcg/kg/min}$. Side effects: Systemic vasodilation, profound hypotension, reduced myocardial contractility. Can cause benign green urine from phenolic metabolites. Propofol Infusion Syndrome (PRIS): Associated with prolonged high-dose infusions ($> 48\,\text{hours}$ at $> 50\,\text{mcg/kg/min}$); characterized by severe metabolic acidosis, rhabdomyolysis, hyperkalemia, acute renal failure, hypertriglyceridemia, and refractory cardiac failure.

  • Dexmedetomidine (Precedex): Selective alpha-2 adrenergic agonist providing sedation, anxiolysis, and analgesia without respiratory depression. Dosage: Optional loading dose of $1\,\text{mcg/kg}$ over $10\,\text{minutes}$ followed by maintenance infusion of $0.2\text{--}1.4\,\text{mcg/kg/hour}$. Patients remain easily arousable; associated with reduced ICU delirium rates. Side effects: Dose-dependent sinus bradycardia and systemic hypotension.

Spontaneous Breathing Trials, Weaning Readiness, and Extubation Protocols

• Readiness Evaluation (Weaning Criteria):

  • Clinical Resolution: Improvement or stability of the primary disease process that led to mechanical ventilation.

  • Oxygenation Parameters: $\text{PaO}_2/\text{FiO}_2 > 150\text{--}200\,\text{mm Hg}$ with $\text{FiO}_2 \le 0.40\text{--}0.50$ and PEEP $\le 5\text{--}8\,\text{cm H}_2\text{O}$.

  • Negative Inspiratory Force (NIF) / Maximum Inspiratory Pressure (MIP): Measures neuromuscular diaphragmatic strength. Must be more negative than $-20\,\text{cm H}_2\text{O}$ (e.g., $-25$, $-30$, or $-40\,\text{cm H}_2\text{O}$). Normal physiological range is $-70\text{ to }-90\,\text{cm H}_2\text{O}$.

  • Vital Capacity (VC): Maximum volume exhaled following full inspiration; must be $> 10\,\text{mL/kg}$.

  • Spontaneous Tidal Volume ($V_{\text{t,spont}}$: Must be $> 5\,\text{mL/kg}$.

  • Minute Ventilation ($V_{\text{e}}$: Total volume exchanged per minute; must be $< 10\,\text{L/min}$ (normal range $5\text{--}10\,\text{L/min}$.

  • Rapid Shallow Breathing Index (RSBI):

  • Formula: $\text{RSBI} = \frac{\text{Respiratory Rate (breaths/min)}}{\text{Tidal Volume (liters)}}$

  • Threshold: An $\text{RSBI} < 105\,\text{breaths/min/L}$ calculated during spontaneous breathing predicts successful extubation.

  • Neurological Readiness: Awake, responsive, capable of tracking commands, intact cough and gag reflexes.

  • Cuff Leak Test: Perform by deflating the endotracheal cuff while auscultating over the trachea. The presence of an audible airflow leak indicates adequate space around the ETT, ruling out critical upper airway edema. Absence of a leak indicates laryngeal swelling, requiring delayed extubation and a short course of intravenous corticosteroids.

• Spontaneous Breathing Trial (SBT) Execution & Failure Indicators:

  • Execution: Discontinue continuous sedation (via SAT); place patient on Pressure Support ($\le 5\text{--}7\,\text{cm H}_2\text{O}$) with low PEEP ($5\,\text{cm H}_2\text{O}$) or a T-piece for a duration of $30\text{ to }120\,\text{minutes}$.

  • Signs of SBT Failure (Trial Termination Triggers):

  • Respiratory Rate: $< 8\,\text{breaths/min}$ or sustained $> 35\,\text{breaths/min}$.

  • Work of Breathing: Accessory muscle usage, abdominal paradox, facial grimacing, diaphoresis.

  • Oxygenation/Ventilation Failure: $\text{SpO}_2 < 90\%$, or acute rise in $\text{EtCO}_2$ (e.g., rising from $35\text{ to }58\,\text{mm Hg}$ over $1\,\text{hour}$) indicating acute hypercapnic hypoventilation.

  • Hemodynamic Instability: SBP $> 180\,\text{mm Hg}$ or $< 90\,\text{mm Hg}$, new tachyarrhythmias, heart rate $> 140\,\text{bpm}$ or a $> 20\%$ shift from baseline.

  • Neurological Deterioration: Sudden agitation, panic, somnolence, or obtundation.

• Post-Extubation Care & Stridor:

  • Continuously monitor respiratory rate, work of breathing, and pulse oximetry.

  • Post-Extubation Stridor: High-pitched inspiratory sound resulting from glottic or subglottic edema.

  • Treatment: Administer aerosolized nebulized racemic epinephrine (stimulates mucosal alpha-1 adrenergic receptors, inducing vasoconstriction and shrinking laryngeal edema) along with supplemental humidified oxygen and intravenous dexamethasone.